Robert DelAversano
Vice President, Finance (Principal Financial Officer and Principal Accounting Officer) at Grace Therapeutics
Executive
About Robert DelAversano
Robert J. DelAversano is Vice President, Finance and the company’s Principal Financial Officer and Principal Accounting Officer at Grace Therapeutics (GRCE). He is a certified public accountant with 26+ years of accounting experience, joined GRCE in November 2023, and is 54 years old as of July 28, 2025 . He reports to CEO Prashant Kohli under a November 12, 2025 employment letter; his compensation includes base salary, a discretionary annual cash bonus, and potential stock options . Company performance context: fiscal 2025 total shareholder return (TSR) measured from a fixed $100 baseline stood at 31.15 and net loss was $9.568 million .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| OncoSec Medical Incorporated | Vice President of Finance; Principal Accounting Officer and Controller; Executive Director of Finance | 2018 – Jul 2023 | Led global accounting, external financial reporting, and financial controls across the business |
| Brio Financial Group | Director of Financial Reporting and Taxation | — | Consulted to public companies on financial reporting, internal controls, budgeting, and forecasting |
| Bartolomei Pucciarelli, LLC | Manager | — | Oversaw accounting and tax practice; industry focuses in manufacturing, wholesalers, and medical device services |
External Roles
- No public company directorships or external board committee roles were disclosed for DelAversano in the proxy’s executive officer biography .
Fixed Compensation
| Component | Terms |
|---|---|
| Base salary | $306,360 annualized (per Nov 12, 2025 letter) |
| Target annual bonus | Up to 30% of base salary, discretionary; must be employed and in good standing on payment date |
| Bonus timing | Paid no later than May 15 following the fiscal year |
| Benefits | Eligible for executive benefit plans per company policy |
| Expense reimbursement | Reimbursed for reasonable, substantiated business expenses |
Performance Compensation
| Incentive | Metric | Weighting | Target | Actual | Payout | Vesting/Timing |
|---|---|---|---|---|---|---|
| Annual cash bonus | Discretionary (company-determined) | n/a | 30% of base salary | Not disclosed | Not disclosed | Pay by May 15 following fiscal year; must be employed/in good standing on pay date |
| Equity | Grant date | Shares | Strike | Vesting schedule | Expiration | Notes |
|---|---|---|---|---|---|---|
| Stock options (potential grant, subject to Board approval) | From time to time | Not disclosed | FMV at grant | Not specified in letter | Not disclosed | Governed by equity plan and option agreement; contingent on continued employment |
| Company practice (reference) | May 6, 2024 (NEOs) | See NEOs | $2.96 | Time-based; quarterly vesting over 36 months | — | Practice for FY2025 NEO grants; not specific to DelAversano |
Note: GRCE’s FY2025 non-DelAversano NEO cash bonus program was tied to corporate milestones (Phase 3 STRIVE ON) and paid 100% of target; this disclosure does not specify DelAversano’s bonus metrics or payout .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Individual beneficial ownership | Not itemized for DelAversano in the beneficial owners table (table lists directors and NEOs; group total for 9 persons is 1,603,359 shares, 11.10%) |
| Hedging policy | Hedging of company stock is prohibited for directors, officers, and employees |
| Clawback | Incentive Compensation Recovery Policy adopted pursuant to Rule 10D-1/Nasdaq |
| Rule 10b5-1 plans | No director or officer adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter ended Sep 30, 2025 |
Employment Terms
| Term | Details |
|---|---|
| Title/role | Vice President, Finance; Principal Financial and Accounting Officer |
| Reports to | CEO Prashant Kohli |
| Letter agreement date | November 12, 2025 |
| Employment start date | Joined GRCE November 2023 |
| Base salary | $306,360 (annualized) |
| Target bonus | Up to 30% of base salary, discretionary |
| Without Cause (no Change in Control) | Severance: 6 months base salary continuation and 6 months COBRA (subject to release), unvested equity forfeited |
| Without Cause within 12 months after Change in Control | Cash: 6 months base salary + target bonus; COBRA: 6 months; unvested equity fully vests and is exercisable (subject to release) |
| Confidentiality/IP | Executed standard Confidentiality of Information and Ownership of Proprietary Property Agreement |
Investment Implications
- Pay structure and metric transparency: Compensation mix is base + discretionary annual bonus + potential options; the letter does not specify explicit bonus performance metrics for DelAversano, limiting pay-for-performance transparency at the individual level . Company-level NEO disclosures show milestone-driven plans, but these are not attributed to DelAversano .
- Retention and change-of-control dynamics: Severance protection of 6 months salary/COBRA absent a change in control is moderate; double-trigger change-of-control benefits add 6 months base plus target bonus and full equity acceleration upon a qualifying termination, which can reduce retention risk pre-close but may create post-transaction selling pressure from accelerated vesting .
- Alignment safeguards: Hedging is prohibited and a Dodd-Frank/Nasdaq-compliant clawback is in place, which are positive governance features for alignment and recourse . No Rule 10b5-1 adoptions/terminations by officers in the September 2025 quarter suggest limited pre-programmed selling signals in that period .
- Ownership visibility: DelAversano’s individual holdings are not itemized in the proxy’s beneficial ownership table (only group totals are shown), constraining a precise assessment of his “skin in the game” and potential selling pressure from vested/unvested holdings .
- Performance backdrop: Fiscal 2025 TSR measured on the SEC-required fixed baseline was 31.15, and net loss was $9.568 million, framing the environment during his tenure; these are company metrics and not individualized performance attributions .
Citations: